IP Library › Granted Patent US 10,844,080
Granted Patent B2
US 10,844,080 · App. 16/827,503 · Granted Nov 24, 2020

Compositions and methods for inhibiting arginase activity

Inventors: Eric B. Sjogren (Mountain View, CA); Jim Li (San Francisco, CA); Michael Van Zandt (Guilford, CT); Darren Whitehouse (Westbrook, CT)
Assignee: CALITHERA BIOSCIENCES, INC.
C07F5/025A61K31/69A61K39/3955A61K39/39533A61K45/06C07K16/2818A61K2039/507
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,844,080
App. No.
16/827,503
Granted
Nov 24, 2020
Kind
B2
Abstract

The invention relates to a novel class of compounds that exhibit activity inhibitory activity toward arginase, and pharmaceutical compositions comprising the compounds of the invention. Also provided herein are methods of treating cancer with the arginase inhibitors of the invention.

Claims (10)

1. A compound that has the structure:

2. A compound that is a pharmaceutically acceptable salt of the compound of claim 1 .

3. The compound of claim 2 , wherein the pharmaceutically acceptable salt is a hydrochloric acid salt, hydrobromic acid salt, sulfuric acid salt, nitric acid salt, perchloric acid salt, phosphoric acid salt, formic acid salt, acetic acid salt, lactic acid salt, maleic acid salt, fumaric acid salt, succinic acid salt, tartaric acid salt, glycolic acid salt, salicylic acid salt, citric acid salt, methanesulfonic acid salt, benzenesulfonic acid salt, benzoic acid salt, malonic acid salt, trifluoroacetic acid salt, trichloroacetic acid salt, naphthalene-2-sulfonic acid salt, oxalic acid salt or mandelic acid salt.

4. The compound of claim 3 , wherein the pharmaceutically acceptable salt is a tartaric acid salt.

5. The compound of claim 4 , which comprises two molecules of the compound of claim 1 per molecule of tartaric acid.

6. A solvate of the compound of claim 2 .

7. The solvate of claim 6 , which is a water solvate, methanol solvate, ethanol solvate or dimethylformamide solvate.

8. A pharmaceutical composition that comprises a compound of claim 1 or a pharmaceutically acceptable salt thereof.

9. A pharmaceutical composition that comprises a compound of claim 2 or a pharmaceutically acceptable salt thereof.

10. A pharmaceutical composition that comprises a compound of claim 4 or a pharmaceutically acceptable salt thereof.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 28, 2023
From: CALITHERA BIOSCIENCES, INC.
To: PRECISION PHARMACEUTICALS, INC.
Reel/Frame 064091/0777 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 25, 2020
From: SJOGREN, ERIC B.; LI, JIM; VAN ZANDT, MICHAEL; WHITEHOUSE, DARREN
To: CALITHERA BIOSCIENCES, INC.
Reel/Frame 053893/0805 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 25, 2020
From: VAN ZANDT, MICHAEL; WHITEHOUSE, DARREN
To: NEW ENGLAND DISCOVERY PARTNERS, LLC
Reel/Frame 053893/0818 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 25, 2020
From: NEW ENGLAND DISCOVERY PARTNERS, LLC
To: CALITHERA BIOSCIENCES, INC.
Reel/Frame 053893/0833 →
Continuity (6)
Continuation 16101275 · Aug 10, 2018
Division 15337041 · Oct 28, 2016
Provisional Application 62323034 · Apr 15, 2016
Provisional Application 62281964 · Jan 22, 2016
Provisional Application 62248632 · Oct 30, 2015
Related Publication 20200223872A1 · Jul 16, 2020